About KREATECH
"No drug is developed, no disease is diagnosed without the essential help of labeling and detection technologies"
KREATECH Holding B.V is a biotechnology company focused on the development, manufacturing and commercialization of innovative labeling and detection products for diagnostic and research applications in the life sciences and healthcare industry. The company is located in Amsterdam, The Netherlands and has approximately 20 employees. KREATECH owns a unique and proprietary technology; the Universal Linkage System (ULS™). This ULS system allows non-enzymatic, direct labeling and detection of DNA, RNA and proteins. In a broad range of applications ULS technology has been proven to generate equal or higher quality data than existing technologies. It is flexible, fast, easy to use and ideally suited to automation for high throughout needs. Whilst the possible applications of ULS are extensive, KREATECH focuses its activities in three main areas, DNA arrays, Proteomic applications and Molecular Diagnostics.
KREATECH is positioned as a strategic partner for drug discovery, pharmaceutical, diagnostic and life science companies.
- Focus : Manufacturer
- Industry : Biotechnology
Product portfolio of KREATECH
Here you will find KREATECH Holding B.V.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous